Moneyball Medicine ─ Thriving in the New Data-driven Healthcare Market

A revolution is transforming the $10 trillion healthcare landscape. Spurred by new laws, new data, and new analytical tools, the way care is delivered is changing radically. Healthcare was once characterized by secrecy, the jealous guarding of patient records, and "the doctor knows best" attitude. But we are quickly moving to a system were troves of data are being combined and mined to determine the best treatments for particular patients and better management of their overall health. In this new landscape, data will determine who gets which treatment. It will also separate the winners from the losers.

Concerns about privacy, heavy regulation, a longstanding culture of secrecy, and ultra-competitiveness have hamstrung the field. Doctors and hospitals guarded patient records, price transparency was unheard of, no one could agree on "fair" ways to measure quality, and researchers in public and private institutions held fast to most of their data, fearing that someone would use it to "scoop them" in the competitive world of medical publishing. Additionally, the Affordable Care Act, increasing pressure to reduce health costs, and giant steps forward in healthcare information technology are having unprecedented impact. Healthcare is finally being revolutionized and disrupted.

This book, which includes interviews of dozens of healthcare leaders, describes the business challenges and opportunities arising for those working in this, one of the largest and now most vibrant sectors of the world’s economy. Doctors, hospital administrators and health information technology directors and entrepreneurs need to adapt to the changes effecting healthcare today in order to succeed in the new, more "cost-conscious" and results-based" environment. The authors maps out many of the changes taking place, how they are influencing the stakeholders, and how likely they are to move quickly or slowly.

Harry Glorikian is an influential global business expert with more than three decades of experience building successful ventures in North America, Europe, Asia and the rest of the world. Harry is well known for achievements in life sciences, healthcare, healthcare IT and the convergence of these areas.He is a sought after speaker, frequently quoted in the media, and regularly asked to assess, influence, and be part of innovative concepts and trends.He holds four US patents in telecommunications, and has others pending.

He recently served as anEntrepreneurIn Residence to GE Ventures – New Business Creation Group. He also serves on the boards of GeneNews Ltd. (a molecular diagnostic company) and Interpace Diagnostics (a molecular diagnostic company). He also serves on the advisory board of Nucelis (a gene-editing industrial biotech company), Evidation Health (a digital health startup launched with support from GE Ventures), and several other companies. He is also a co-founder and an advisory board memberof ?DrawBridge Health (a revolutionary diagnostics startup launched with support from GE Ventures).

Previously he co-founded and held the position of managing director and head of consulting services for Scientia Advisors, a company that became the go-to provider of strategic advice and implementation services for next-generation healthcare and life science innovators and Global 25 market leaders. Scientia Advisors was acquired by Precision for Medicine in November of 2012. Among his other professional roles, Mr. Glorikian served as senior manager for global business development at PE Applied Biosystems, founded X-Cell Laboratories, managed global sales at Signet Laboratories and held various roles at BioGenex Laboratories.

Mr. Glorikian holds an MBA from Boston University and a bachelor's degree from San Francisco State University.Harry has addressed the National Institutes of Health, Molecular Medicine Tri-Conference, World Theranostics Congress and other audiences, worldwide. He has authored numerous articles for industry publications, appeared on CBS Evening News and been quoted regularly by Dow Jones,The Boston Globe, BioWorld Today, Los Angeles Times, London Independent, Medical Device Daily, Science Magazine, Genetic Engineering News and many other media outlets.

Malorye Allison Branca is an award-winning medical science writer who has been reporting on healthcare topics for more than 20 years. Her by-lined articles have appeared in publications that include Bio-ITWorld, The Harvard Health Letter, Harvard Magazine, Science, Nature Biotechnology, Nature Reviews in Drug Discovery, and The Pink Sheet.

She specializes in writing about how new technologies and approaches are impacting progress and markets all the way from drug discovery through healthcare delivery. Malorye has also created content for several websites, done market analysis and forecasting, launched several publications, drafted press releases and scientific articles, and written grant proposals and associated materials for a recently-founded healthcare non-profit (Grameen Health/Grameen VidaSana).

Malorye has also worked as a ghostwriter for individuals such as the co-founder of one of the world’s largest medical device companies, a Nobel Peace Laureate, a former health benefits executive at Walmart, the founder at a biotechnology investment fund, and the chancellor of a medical school. Those works have included blog posts, white papers, book chapters, editorials and posts for Linked In. Editorials that Malorye has worked on have appeared in publications that include The Wall Street Journal, The Financial Times, and Xconomy. She has a BS from Colorado State University and an MS from the Harvard University Extension.